S&P 500   4,609.86 (+0.94%)
DOW   34,692.55 (+0.61%)
QQQ   395.63 (+0.46%)
AAPL   169.07 (+2.28%)
MSFT   335.38 (+1.45%)
FB   317.69 (-2.09%)
GOOGL   2,874.05 (+1.27%)
AMZN   3,501.86 (-0.15%)
TSLA   1,140.00 (-0.42%)
NVDA   323.05 (-1.14%)
BABA   124.86 (-2.09%)
NIO   39.54 (+1.05%)
CGC   10.31 (-3.73%)
AMD   154.32 (-2.56%)
GE   95.31 (+0.34%)
MU   87.40 (+4.05%)
T   22.59 (-1.05%)
F   20.00 (+4.22%)
DIS   144.89 (+-0.01%)
PFE   54.49 (+1.41%)
ACB   6.24 (-2.80%)
AMC   32.28 (-4.89%)
BA   193.79 (-2.05%)
S&P 500   4,609.86 (+0.94%)
DOW   34,692.55 (+0.61%)
QQQ   395.63 (+0.46%)
AAPL   169.07 (+2.28%)
MSFT   335.38 (+1.45%)
FB   317.69 (-2.09%)
GOOGL   2,874.05 (+1.27%)
AMZN   3,501.86 (-0.15%)
TSLA   1,140.00 (-0.42%)
NVDA   323.05 (-1.14%)
BABA   124.86 (-2.09%)
NIO   39.54 (+1.05%)
CGC   10.31 (-3.73%)
AMD   154.32 (-2.56%)
GE   95.31 (+0.34%)
MU   87.40 (+4.05%)
T   22.59 (-1.05%)
F   20.00 (+4.22%)
DIS   144.89 (+-0.01%)
PFE   54.49 (+1.41%)
ACB   6.24 (-2.80%)
AMC   32.28 (-4.89%)
BA   193.79 (-2.05%)
S&P 500   4,609.86 (+0.94%)
DOW   34,692.55 (+0.61%)
QQQ   395.63 (+0.46%)
AAPL   169.07 (+2.28%)
MSFT   335.38 (+1.45%)
FB   317.69 (-2.09%)
GOOGL   2,874.05 (+1.27%)
AMZN   3,501.86 (-0.15%)
TSLA   1,140.00 (-0.42%)
NVDA   323.05 (-1.14%)
BABA   124.86 (-2.09%)
NIO   39.54 (+1.05%)
CGC   10.31 (-3.73%)
AMD   154.32 (-2.56%)
GE   95.31 (+0.34%)
MU   87.40 (+4.05%)
T   22.59 (-1.05%)
F   20.00 (+4.22%)
DIS   144.89 (+-0.01%)
PFE   54.49 (+1.41%)
ACB   6.24 (-2.80%)
AMC   32.28 (-4.89%)
BA   193.79 (-2.05%)
S&P 500   4,609.86 (+0.94%)
DOW   34,692.55 (+0.61%)
QQQ   395.63 (+0.46%)
AAPL   169.07 (+2.28%)
MSFT   335.38 (+1.45%)
FB   317.69 (-2.09%)
GOOGL   2,874.05 (+1.27%)
AMZN   3,501.86 (-0.15%)
TSLA   1,140.00 (-0.42%)
NVDA   323.05 (-1.14%)
BABA   124.86 (-2.09%)
NIO   39.54 (+1.05%)
CGC   10.31 (-3.73%)
AMD   154.32 (-2.56%)
GE   95.31 (+0.34%)
MU   87.40 (+4.05%)
T   22.59 (-1.05%)
F   20.00 (+4.22%)
DIS   144.89 (+-0.01%)
PFE   54.49 (+1.41%)
ACB   6.24 (-2.80%)
AMC   32.28 (-4.89%)
BA   193.79 (-2.05%)
NASDAQ:MYGN

Myriad Genetics Stock Forecast, Price & News

$25.92
+0.06 (+0.23%)
(As of 12/1/2021 01:15 PM ET)
Add
Compare
Today's Range
$25.88
$26.65
50-Day Range
$25.86
$34.76
52-Week Range
$17.18
$36.95
Volume
13,928 shs
Average Volume
600,015 shs
Market Capitalization
$2.07 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.51
30 days | 90 days | 365 days | Advanced Chart
Receive MYGN News and Ratings via Email

Sign-up to receive the latest news and ratings for Myriad Genetics and its competitors with MarketBeat's FREE daily newsletter.


Myriad Genetics logo

About Myriad Genetics

Myriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic test. It operates through the Diagnostics and Other segments. The Diagnostics segment provides testing and collaborative development of testing that is designed to asses an individual's risk of developing a disease later in life. The Other segment offers testing products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients; and also includes corporate services. The company was founded by Walter A. Gilbert, Mark H. Skolnick, and Peter D. Meldrum in May 1991 and is headquartered in Salt Lake City, UT.

Headlines

Myriad Genetics Reaches Analyst Target Price
November 9, 2021 |  nasdaq.com
Myriad Genetics Names Pamela Wong as Chief Legal Officer
October 18, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry
Diagnostic substances
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:MYGN
CUSIP
62855J10
Employees
2,700
Year Founded
1991

Sales & Book Value

Annual Sales
$638.60 million
Cash Flow
$0.12 per share
Book Value
$12.13 per share

Profitability

Net Income
$-44.20 million
Pretax Margin
-10.13%

Debt

Price-To-Earnings

Miscellaneous

Free Float
78,497,000
Market Cap
$2.07 billion
Optionable
Optionable

Company Calendar

Last Earnings
11/02/2021
Today
12/01/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
2/22/2022

Social Links


MarketRank

Overall MarketRank

1.71 out of 5 stars

Medical Sector

907th out of 1,392 stocks

Diagnostic Substances Industry

13th out of 25 stocks

Analyst Opinion: 1.8Community Rank: 3.6Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -












Myriad Genetics (NASDAQ:MYGN) Frequently Asked Questions

Is Myriad Genetics a buy right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Myriad Genetics in the last year. There are currently 1 sell rating and 2 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Myriad Genetics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MYGN, but not buy additional shares or sell existing shares.
View analyst ratings for Myriad Genetics
or view top-rated stocks.

How has Myriad Genetics' stock price been impacted by COVID-19 (Coronavirus)?

Myriad Genetics' stock was trading at $14.03 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, MYGN stock has increased by 87.7% and is now trading at $26.33.
View which stocks have been most impacted by COVID-19
.

When is Myriad Genetics' next earnings date?

Myriad Genetics is scheduled to release its next quarterly earnings announcement on Tuesday, February 22nd 2022.
View our earnings forecast for Myriad Genetics
.

How were Myriad Genetics' earnings last quarter?

Myriad Genetics, Inc. (NASDAQ:MYGN) announced its quarterly earnings results on Tuesday, November, 2nd. The company reported ($0.02) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.02). The firm had revenue of $167.30 million for the quarter, compared to analyst estimates of $164.35 million. Myriad Genetics had a negative trailing twelve-month return on equity of 3.71% and a negative net margin of 9.32%. During the same period last year, the company posted ($0.19) EPS.
View Myriad Genetics' earnings history
.

What price target have analysts set for MYGN?

3 brokerages have issued 12-month target prices for Myriad Genetics' shares. Their forecasts range from $25.00 to $35.00. On average, they anticipate Myriad Genetics' stock price to reach $30.00 in the next twelve months. This suggests a possible upside of 13.9% from the stock's current price.
View analysts' price targets for Myriad Genetics
or view top-rated stocks among Wall Street analysts.

Who are Myriad Genetics' key executives?

Myriad Genetics' management team includes the following people:
  • Paul J. Diaz, President, Chief Executive Officer & Director
  • R. Bryan Riggsbee, Chief Financial Officer, Treasurer & Executive VP
  • Jerry S. Lanchbury, Chief Scientific Officer
  • Kevin R. Haas, Chief Technology Officer
  • Thomas P. Slavin, Chief Medical Officer

What is Paul Diaz's approval rating as Myriad Genetics' CEO?

12 employees have rated Myriad Genetics CEO Paul Diaz on Glassdoor.com. Paul Diaz has an approval rating of 74% among Myriad Genetics' employees.

What other stocks do shareholders of Myriad Genetics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Myriad Genetics investors own include Micron Technology (MU), Advanced Micro Devices (AMD), NVIDIA (NVDA), Gilead Sciences (GILD), BioMarin Pharmaceutical (BMRN), Incyte (INCY), Puma Biotechnology (PBYI), AT&T (T), Alibaba Group (BABA) and Kratos Defense & Security Solutions (KTOS).

What is Myriad Genetics' stock symbol?

Myriad Genetics trades on the NASDAQ under the ticker symbol "MYGN."

Who are Myriad Genetics' major shareholders?

Myriad Genetics' stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (17.37%), Wellington Management Group LLP (4.05%), Camber Capital Management LP (3.44%), Dimensional Fund Advisors LP (3.36%), Glenview Capital Management LLC (2.80%) and Goldman Sachs Group Inc. (2.73%). Company insiders that own Myriad Genetics stock include Alexander Ford, Daniel K Spiegelman, Dennis Langer, Jayne B Hart, Jerry S Lanchbury, Jerry S Lanchbury, Nicole Lambert, Paul Parkinson, Richard Bryan Riggsbee, S Louise Phanstiel and Walter Phd Gilbert.
View institutional ownership trends for Myriad Genetics
.

Which major investors are selling Myriad Genetics stock?

MYGN stock was sold by a variety of institutional investors in the last quarter, including Two Sigma Advisers LP, Camber Capital Management LP, Glenview Capital Management LLC, Millennium Management LLC, Point72 Asset Management L.P., Goldman Sachs Group Inc., Dimensional Fund Advisors LP, and Citigroup Inc.. Company insiders that have sold Myriad Genetics company stock in the last year include Daniel K Spiegelman, Dennis Langer, Jayne B Hart, Jerry S Lanchbury, Nicole Lambert, Paul Parkinson, Richard Bryan Riggsbee, and S Louise Phanstiel.
View insider buying and selling activity for Myriad Genetics
or view top insider-selling stocks.

Which major investors are buying Myriad Genetics stock?

MYGN stock was bought by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Polar Asset Management Partners Inc., Artisan Partners Limited Partnership, CastleArk Alternatives LLC, Nordea Investment Management AB, Balyasny Asset Management LLC, Renaissance Technologies LLC, and Allianz Asset Management GmbH. Company insiders that have bought Myriad Genetics stock in the last two years include S Louise Phanstiel, and Walter Phd Gilbert.
View insider buying and selling activity for Myriad Genetics
or or view top insider-buying stocks.

How do I buy shares of Myriad Genetics?

Shares of MYGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Myriad Genetics' stock price today?

One share of MYGN stock can currently be purchased for approximately $26.33.

How much money does Myriad Genetics make?

Myriad Genetics has a market capitalization of $2.10 billion and generates $638.60 million in revenue each year. The company earns $-44.20 million in net income (profit) each year or ($0.87) on an earnings per share basis.

How many employees does Myriad Genetics have?

Myriad Genetics employs 2,700 workers across the globe.

Does Myriad Genetics have any subsidiaries?

The following companies are subsidiares of Myriad Genetics: AssureRx Canada Ltd, Assurex Health Inc., Crescendo Bioscience Inc, Javelin Pharmaceuticals, MVZ Fur Molekulardiagnostik GmbH, Myriad Autoimmune, Myriad Genetic Laboratories Inc., Myriad Genetics Australia PTY LTD, Myriad Genetics B.V., Myriad Genetics Canada Corp, Myriad Genetics Espana SL, Myriad Genetics GmbH, Myriad Genetics LTD, Myriad Genetics S.r.l., Myriad Genetics SAS, Myriad GmbH, Myriad International GmbH, Myriad Neuroscience, Myriad RBM Inc., Myriad Services GmbH, Myriad Women’s Health, NaturNorth Technologies, Privatklinik Dr. Robert Schindlbeck, Privatklinik Dr. Robert Schindlbeck GmbH & Co. KG, Rules-Based Medicine, and Sividon Diagnostics.

When was Myriad Genetics founded?

Myriad Genetics was founded in 1991.

What is Myriad Genetics' official website?

The official website for Myriad Genetics is www.myriad.com.

Where are Myriad Genetics' headquarters?

Myriad Genetics is headquartered at 320 WAKARA WAY, SALT LAKE CITY UT, 84108.

How can I contact Myriad Genetics?

Myriad Genetics' mailing address is 320 WAKARA WAY, SALT LAKE CITY UT, 84108. The company can be reached via phone at (801) 584-3600, via email at [email protected], or via fax at 801-584-3640.


This page was last updated on 12/1/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.